A clinical study in the Knight-ADRC (n = 311) and ADNI (N = 293) cohorts previously showed that CSF ANGPT-2 level was strongly associated with the ratio of ptau181:Aβ42 – a predictor of conversion from unimpaired cognition to very mild/mild AD [29]. This evidence concerns the gene ANGPT2 and Alzheimer disease.